Vanguard Global Advisers
RCUS icon

Vanguard Global Advisers’s Arcus Biosciences RCUS Stock Holding History

Vanguard Global Advisers’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.25M Sell
40,500
-1,496
-4% -$37K ﹤0.01% 1602
2026
Q1 		$907K Buy
+41,996
New +$907K ﹤0.01% 1711

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Vanguard Global Advisers's RCUS Position: Q2 2026 in Review

Vanguard Global Advisers reduced its Arcus Biosciences (RCUS) stake by 3.6% in Q2 2026, selling an estimated $37K and leaving 40,500 shares worth $1.25M. The position accounts for ﹤0.01% of the portfolio, ranked #1602.

Vanguard Global Advisers first reported a position in RCUS in Q1 2026 and has held it in 2 quarters since. 229 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

  • Vanguard Global Advisers held 40,500 shares of Arcus Biosciences worth $1.25M as of Q2 2026.
  • Vanguard Global Advisers sold 1,496 Arcus Biosciences shares in Q2 2026, an estimated $37K.
  • Arcus Biosciences made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #1602 holding.
  • Vanguard Global Advisers first reported a position in Arcus Biosciences in Q1 2026 and has held it in 2 quarters since.
  • 229 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.